Global research trends on ALK-TKIs in non-small cell lung cancer: a bibliometric analysis
BackgroundLung cancer remains the leading cause of cancer-related incidence and mortality worldwide. Non-small cell lung cancer (NSCLC) constitutes the most prevalent histological subtype of lung cancer. A notable proportion of NSCLC patients harbor mutations in the anaplastic lymphoma kinase (ALK)...
Saved in:
| Main Authors: | Yafeng Liu, Zhaojin Han, Yujia Li, Pengfei Zhang, Qiushi Wang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1665174/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
by: Peng Song, et al.
Published: (2020-05-01) -
Efficacy and safety analysis of lorlatinib for ALK-positive advanced NSCLC: a multicentre real-world study in China
by: Zhujun Chen, et al.
Published: (2025-07-01) -
Vulnerability of drug‐resistant EML4‐ALK rearranged lung cancer to transcriptional inhibition
by: Athanasios R Paliouras, et al.
Published: (2020-06-01) -
A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
by: Yue Lu, et al.
Published: (2021-11-01) -
Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA
by: Simon Heeke, PhD, et al.
Published: (2025-04-01)